Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Carcinoma, Transitional Cell 16Urinary Bladder Neoplasms 15Carcinoma, Merkel Cell 10Neoplasm Metastasis 8Carcinoma, Renal Cell 8Breast Neoplasms 8Neoplasms 6Triple Negative Breast Neoplasms 5Melanoma 5Ureteral Neoplasms 4Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urethral Neoplasms 3Skin Neoplasms 3Prostatic Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Neuroendocrine Tumors 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Urothelial Cancer 1Turcot syndrome 1Thymoma 1

Interventions

pembrolizumab 88Carboplatin 77Specimen Handling 76Magnetic Resonance Spectroscopy 63Pemetrexed 59Cisplatin 47durvalumab 44Paclitaxel 38Nivolumab 34atezolizumab 32osimertinib 29Radiotherapy 29Radiosurgery 29Biopsy 26Blood Specimen Collection 25Gemcitabine 24Docetaxel 24Immunoglobulin G 23Disulfides 22Standard of Care 21Drug Therapy 21Etoposide 19Taxes 18Practice Guidelines as Topic 18Radiation 17Educational Status 16130-nm albumin-bound paclitaxel 15X-Rays 14Surveys and Questionnaires 14Bevacizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × avelumab × 1 year × Clear all
NCT04902040 2026-04-30

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

M.D. Anderson Cancer Center

Phase 1/2 Terminated
19 enrolled 11 charts
GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡